Aquestive Therapeutics, Inc. (AQST) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Aquestive Therapeutics is a pharmaceutical company operating as both a developer of proprietary products and a Contract Development and Manufacturing Organization (CDMO). The company is a "smaller reporting company" and a "non-accelerated filer." Its primary focus includes the advancement of Anaphylm (dibutepinephrine) for anaphylaxis and AQST-108 for dermatological conditions, alongside manufacturing licensed products such as Suboxone.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in thousands) |
|---|---|
| Total Revenues | $28,265 |
| Net Loss | $(30,921) |
| Loss Per Share (Basic & Diluted) | $(0.25) |
| Cash and Cash Equivalents | $98,490 |
| Total Debt (Long-term, net) | $50,654 |
| Net Cash Used in Operating Activities | $(24,247) |
| Stockholders' Deficit | $(56,586) |
Note: The company reported a significant one-time loss on extinguishment of debt of $11,683 due to the refinancing of its 13.5% Notes.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 51% to $28.3 million compared to $18.7 million in the prior year period. This was driven by a 23% increase in manufacture and supply revenue (primarily Suboxone) and a 313% surge in license and royalty revenue (driven by a $5.0 million royalty recognition from Zevra).
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased 21% to $25.0 million, largely due to lower commercial spending and the absence of a one-time PDUFA fee incurred in the prior year. R&D expenses decreased 14% to $8.2 million.
- Debt Refinancing: In May 2026, the company entered into a new $150 million Term Loan Facility with Oaktree Capital Management. It drew down the initial $55 million tranche to repay the outstanding $45 million 13.5% Notes, incurring a prepayment penalty and exit fees that resulted in the $11.7 million loss on extinguishment.
- Liquidity: Cash balances decreased by $22.7 million during the period, ending at $98.5 million. This reduction reflects operating cash burn and debt repayment costs, partially offset by proceeds from the new term loan and ATM equity sales.
Guidance, Outlook, and Risks
- Anaphylm Regulatory Status: The company received a Complete Response Letter (CRL) from the FDA in January 2026 regarding human factors (HF) validation. The company conducted new HF and PK studies in Q2 2026 showing significant improvements (e.g., pouch opening time reduced from 17 to 3 seconds). A resubmission of the New Drug Application (NDA) is planned for Q3 2026, with a request for accelerated review.
- Libervant Market Access: U.S. market access for Libervant (diazepam buccal film) for pediatric patients (ages 2-5) remains "tentative" following a District Court ruling in favor of competitor Neurelis regarding Orphan Drug Exclusivity. The company is appealing this decision and has ceased U.S. marketing activities pending the outcome. Legislative changes in February 2026 may support the company's position.
- Liquidity Outlook: Management states that existing cash, the new Term Loan Facility, and access to the ATM facility provide sufficient liquidity to fund operations for at least the next 12 months.
- Key Risks:
- Failure to obtain FDA approval for Anaphylm or Libervant.
- Dependence on Indivior (Suboxone) for a significant portion of revenue (approx. 70% in H1 2026).
- Substantial debt obligations and interest expenses, including royalty obligations tied to future sales.
- Ongoing litigation, including product liability suits regarding Suboxone and securities class actions filed in March 2026.
Investor Verification Checklist
- Debt Covenants: Verify the specific financial covenants and minimum net sales requirements attached to the new Oaktree Term Loan Facility, particularly regarding the drawdown of Tranche B and C.
- Anaphylm Resubmission: Confirm the timeline and FDA acceptance of the planned Q3 2026 NDA resubmission following the CRL.
- Libervant Litigation: Monitor the status of the appeal regarding the District Court's vacatur of Libervant's approval and the impact of the February 2026 Orphan Drug Act amendments.
- Customer Concentration: Assess the risk exposure related to Indivior, which accounted for approximately 70% of total revenue in the first half of 2026.
- Securities Litigation: Review the progress of the securities class action filed in March 2026 alleging misstatements regarding the Anaphylm NDA.